Navigation Links
Gene therapy research from Penn Vet & Scheie Eye Inst. cures retinitis pigmentosa in dogs
Date:1/23/2012

PHILADELPHIA -- Members of a University of Pennsylvania research team have shown that they can prevent, or even reverse, a blinding retinal disease, X-linked Retinitis Pigmentosa, or XLRP, in dogs.

The disease in humans and dogs is caused by defects in the RPGR gene and results in early, severe and progressive vision loss. It is one of the most common inherited forms of retinal degeneration in man.

"Every single abnormal feature that defines the disease in the dogs was corrected following treatment," said lead author William Beltran, assistant professor of ophthalmology at Penn's School of Veterinary Medicine.

"We were thrilled," said senior author Gustavo Aguirre, professor of medical genetics and ophthalmology at Penn Vet. "The treated cells were completely normal, and this effect resulted from introducing the normal version of the human gene into the diseased photoreceptor cells."

The similarities between humans and dogs, in terms of both eye anatomy, physiology, disease characteristics and positive response to this gene therapy, raise hope for a clear path to human therapies.

Beltran and Aguirre collaborated with Artur Cideciyan and Samuel Jacobson at the Scheie Eye Institute, part of the University of Pennsylvania's Perelman School of Medicine. This achievement results from more than 10 years of close collaboration between the scientists at Penn's veterinary and medical Schools and the University of Florida.

In addition to others at Penn Vet, Scheie and Florida, researchers at the universities of Michigan and Massachusetts and the National Eye Institute at the National Institutes of Health contributed to the research.

The study will be published in the journal Proceedings of the National Academy of Sciences.

The gene therapy approach used takes advantage of a viral vector a genetically modified virus that doesn't cause disease and is unable to divide -- to deliver the
'/>"/>

Contact: Evan Lerner
elerner@upenn.edu
215-573-6604
University of Pennsylvania
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
2. Reliant Technologies Announces Canadian Launch of Fraxel re:pair(R) Laser: A New Class of Treatment Therapy for CO2 Laser Skin Resurfacing
3. FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting
4. Regenerative Medicine Appoints Cell Therapy Group Consultant to Editorial Board
5. Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
6. Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems
7. Progenitor Cell Therapy Secures Industry Accreditation
8. Nucletron Announces Market Release of First Commercially Available Software to Review and Share Dicom-Based Treatment Plans for Radiotherapy
9. Doctors in the US and Netherlands Using Fast RapidArc Radiotherapy Technology to Help Fight Cancer are Now Treating Tumors of the Head and Neck
10. First Coast Oncology to Offer Next Generation Proton Therapy
11. Varian to Showcase RapidArc(TM) Radiotherapy Technology Enhancements at ASTRO 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Apache Junction, AZ (PRWEB) June 02, 2015 ... of light microscope technology, Yancy Corporation is ... with any desired material and biological sample, displaying the ... and electron bonds between atoms. , Jeff Porter, Co-Founder ... new physics are just that – rare. They come ...
(Date:6/2/2015)... 2, 2015 MGB Biopharma ... resistance problem  MGB Biopharma, a biopharmaceutical ... to address the major global problem of antibiotic ... stable intravenous (IV) formulation of MGB-BP-3, designed for the ... The intravenous formulation of MGB-BP-3 is ...
(Date:6/2/2015)... June 02, 2015 German-based Moenninghoff has ... States distributor for the Moenninghoff product line . ... am pleased to announce that the R.M. Hoffman Company ... our firm, founded in 1916, this is a strategically ... is the kind of professional distributor we need to ...
(Date:6/2/2015)... Orleans, LA (PRWEB) June 02, 2015 ... custom gene synthesis to improve protein expression, announced the ... board includes six executives and entrepreneurs with a broad ... software industries. , The team includes: , Jimmy ... Fund: , Roussel has a background in technology and ...
Breaking Biology Technology:Scientists Eying Rare Discovery Of New Physics & Light Microscope Technology 2MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 2MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 3R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 2R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 3GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 2GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 3
... New statistics just released reveal that R&D investment in ... in 2008, an increase of 3 percent from 2007, ... Company, a San Francisco based global leader in life ... Equity, Merchant Banking and Media and the Washington DC-based ...
... March 10 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ... Annual Health Care Conference on Tuesday, March 17, ... Boston. Daniel M. Bradbury, president and chief executive officer ... presentation and breakout session will be webcast, and a recording ...
... FM53 mask with its ISI developed SCBA systemBALTIMORE, March ... respiratory protection, Avon Protection Systems - a subsidiary of ... for Occupational Safety and Health) approval for its new ... division. The ST53 system combines Avon,s tactical FM53 dual ...
Cached Biology Technology:R&D Spending by U.S. Biopharmaceutical Companies Increases 3 Percent in 2008 2R&D Spending by U.S. Biopharmaceutical Companies Increases 3 Percent in 2008 3Avon Protection Systems Receives NIOSH Approval for ST53 SCBA System 2Avon Protection Systems Receives NIOSH Approval for ST53 SCBA System 3
(Date:6/1/2015)... -- According to a new market research ... (Touch-based & Touchless), Application (Consumer Electronics, Automotive, & Others), ... Global Forecast to 2020", published by MarketsandMarkets, the Gesture ... $23.55 Billion by 2020, at a CAGR of 28.23% ... market data T ables and   86   ...
(Date:6/1/2015)... 1, 2015 According to ... Market by Application (Government, Military & Defense, Healthcare, ... and Security), Technology (Face Recognition, Fingerprint Recognition, Iris ... Recognition, and Others), Function (Contact and Non-Contact) & ... Europe , APAC, Row) - Global ...
(Date:5/29/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ... "Facial Recognition Market by Solution, by Software, by ... 2020" report to their offering. ... technology become more efficient and cost effective. This ... investment from the commercial sector. The development of ...
Breaking Biology News(10 mins):Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 2Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 3Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 4Next Generation Biometrics Market Worth $24,448.84 Million by 2020 2Next Generation Biometrics Market Worth $24,448.84 Million by 2020 3Next Generation Biometrics Market Worth $24,448.84 Million by 2020 4Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2
... sulfate supplementation before preterm delivery cuts the risk for ... by University of Alabama at Birmingham (UAB) obstetrician Dwight ... of The New England Journal of Medicine. , ... affecting control of movement and posture and limiting activity. ...
... Genetics, and working in conjunction with Society in ... exploring new avenues in the relationship between science and ... where authorship really matters. Based on a powerful authorship ... to its corresponding author. In this way readers can ...
... A 75-million-year-old fossil of a pregnant turtle and a nest ... southeastern Alberta by scientists and staff from the University of ... ideas on the evolution of egg-laying and reproduction in turtles ... of a pregnant turtle has been found and the description ...
Cached Biology News:Common treatment to delay labor decreases preterm infants' risk for cerebral palsy 2Common treatment to delay labor decreases preterm infants' risk for cerebral palsy 3ETH Zurich-administered fund ends scientific anonymity 2Ancient mother spawns new insight on reptile reproduction 2
... Immunogen: Synthetic peptide derived from the ... 36 protein This peptide sequence is ... another Zymed polyclonal Connexin 36 antibody Cat. ... Connexin 36. Reactivity: Mouse (positive control: ...
Invitrogen's Calcium Phosphate Transfection Kit provides high-quality reagents to enable the introduction of DNA into tissue culture cells via calcium phosphate co-precipitation....
...
...
Biology Products: